MassChallenge

Extracellular specializes in research and development platforms and biomanufacturing solutions aimed at enhancing the sustainable biotech ecosystem. The company leverages its expertise in cellular behavior and scale-up processes to efficiently produce biomass for cultivated meat and seafood, as well as for applications in plant cell culture, bio-cosmetics, bio-supplements, and bio-materials. By digitalizing process development and aggregating extensive data, Extracellular facilitates improved decision-making and accelerates the commercialization of biotech innovations. The focus is on reducing research and development costs and timelines, enabling sustainable biotech companies to bring their products to market more rapidly through efficient and cost-effective cellular agriculture practices at scale.

Nature's Principle, originating from a Ph.D. project at Delft University of Technology in the Netherlands, specializes in a patented mixed culture fermentation technology that aims to revolutionize traditional agro-chemical production methods. This innovative process effectively converts low-value waste streams, including sugar beet, pulp, and molasses, into valuable products such as lactic acid and poly-lactic acid, which can be utilized in food preservation and bioplastics. By leveraging natural principles to cultivate microorganisms, the company enhances their productivity without resorting to genetic engineering. This approach allows clients to replace oil-based chemicals, offering significant advantages in water consumption, carbon dioxide emissions, and land usage, thereby promoting more sustainable production practices.

SCALE Advanced Biocomposites specializes in the development of natural-fiber composites aimed at advancing the use of bio-based materials across various industries, including sporting goods, automotive, wind power, and aerospace. The company's innovative materials and technologies offer an effective alternative to carbon fiber, enhancing performance while simultaneously reducing costs and greenhouse gas emissions. This approach supports clients in their efforts to decarbonize high-performance composites, contributing to a more sustainable built environment. Through its focus on creating new, bio-based materials, SCALE seeks to significantly lower emissions and promote the adoption of eco-friendly solutions in multiple sectors.

Anviron is a company focused on developing advanced therapies for late-stage cancers. It employs a team of scientists, doctors, and clinicians who work collaboratively to address the challenges posed by difficult-to-treat cancers. By leveraging cutting-edge scientific research, Anviron aims to create innovative therapies that meet the unmet medical needs in oncology. The company's efforts are directed towards improving patient outcomes and transforming the landscape of cancer care.

Speratum is a biopharmaceutical company focused on microRNA-directed oncology therapies. The Company was founded in 2014 by Christian Marín-Müller, Ph.D. and is dedicated to the development of a patented treatment for pancreatic cancer based on the combination of tumor suppressive microRNA molecules and nanoparticle-based drug delivery technologies. The Company is currently entering the final stage of preclinical trials for the pancreatic cancer therapy, while simultaneously expanding the patent’s coverage to incorporate other types of cancer and non-cancer indications and illnesses and expanding its intellectual property (IP) portfolio with complementary technologies in the fields of nanotechnology, medical devices and veterinary medicine.

Cellorama multipurpose devices, reagents, and processes are patent-pending and protect cell structure and integrity during many procedures. User-friendly and cost-effective devices are designed to minimize stressful stages in the laboratory while saving time and vital resources.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Azooka is a biotechnology company focused on manufacturing proprietary fluorophores and molecular biology products for life science research and molecular diagnostics. The company produces a range of fluorescent dyes and tags for applications involving DNA, RNA, chromosomes, and live cells, as well as molecular-grade sample collection and transport mediums. Azooka aims to provide secure and sustainable biotech consumables at affordable prices, making these essential tools accessible to researchers worldwide. Recently, the company was recognized as the "Best Women-Led Enterprise," highlighting its commitment to innovation and leadership in the biotech sector.

Stellate Therapeutics is a private biotechnology company specializing in the development of small molecules derived from human gut bacteria to create personalized therapies for neurological diseases. The company focuses on addressing age-related neurological conditions, particularly through its research on the gut-brain axis. Stellate has developed a portfolio of drug candidates, including AMA-101, which aims to be a first-in-class therapy for Parkinson's disease. Through its microbiome-derived medicine platform, Stellate Therapeutics is engaged in comprehensive research and has established capabilities in discovery, screening, production, and diagnostic development, striving to provide effective treatments for neurological disorders.

Trove Health offers a platform designed to enhance access to patient data for patients, healthcare providers, and life sciences organizations. The company's primary focus is on clinical trial recruitment, where it aims to build a diverse and engaged database of consented participants. By efficiently identifying and recruiting patients who meet specific enrollment criteria across various geographies and therapeutic areas, Trove Health enables researchers to advance medical cures and therapies. Additionally, the platform empowers patients by allowing them to control and potentially monetize their health information while receiving tailored treatments.

Dart Biosciences works in the healthcare industry. It creates tailored gene therapies for a variety of uncommon and prevalent disorders.

Symphony Biosciences is focused on developing innovative cancer therapies aimed at improving treatments for solid tumors, particularly targeting triple-negative breast cancer. This type of cancer currently has limited effective treatment options, primarily relying on toxic chemotherapies that often fail to provide significant survival benefits. By utilizing biomaterials in its research, Symphony Biosciences aims to enhance the immune response against these challenging cancers, ultimately providing healthcare professionals with better tools to treat patients. The company's mission is to improve patient access to effective cancer treatments and address the critical needs within oncology.

Arnav Biotech is a biotechnology company that operates as a Contract Development and Manufacturing Organization (CDMO), specializing in mRNA technology. It offers services for the design, development, and manufacturing of custom and cataloged mRNA products, supporting research, therapeutics, and vaccines. By providing these services, Arnav Biotech enables researchers to concentrate on their specific areas of interest, thereby democratizing access to mRNA-based life sciences.

Skygenic is a cloud-based software platform designed to facilitate the storage and analysis of genomic data, thereby enhancing the research capabilities of scientists. Developed in collaboration with experts from Harvard Medical School and Boston Children's Hospital, the platform aims to simplify the data analysis process for non-programming scientists, enabling them to independently analyze and interpret biological data. By addressing the challenges faced in early-stage and translational research, Skygenic effectively reduces the reliance on bioinformaticians, allowing research to progress more efficiently and economically. This innovation supports academic institutions, hospitals, biotechnology, and pharmaceutical organizations by streamlining workflows and enabling researchers to focus on critical aspects of their work, ultimately accelerating scientific discovery.

Azul Bio specializes in marine ecosystem preservation and restoration, focusing on enhancing the resilience of coral reefs against climate change. The company provides biological analysis services, including DNA-based biodiversity assessments, species genotyping, microbiome profiling, and disease detection, to support marine research, aquaculture, and environmental monitoring.

Nanoplex is a healthcare and life sciences company.

BioBQ is a cultivated meat company focused on producing slaughter-free beef brisket and other BBQ meats from cultured animal cells. Utilizing proprietary technologies, the company efficiently creates whole cuts of meat in weeks, significantly reducing the time compared to traditional cattle farming. This innovative approach not only allows for precise control of meat content and flavor but also minimizes the environmental impact associated with conventional meat production. By offering a sustainable alternative, BioBQ aims to meet the growing consumer demand for tasty and environmentally friendly meat options, ensuring that animal welfare and climate concerns are addressed.

Ronawk is a biotechnology company that specializes in the development of T-Block technology, which produces patient-specific biologics for the treatment of diseases, including cancer, organ injuries, and burns. The company has created a proprietary method for growing primary stem cells in a three-dimensional environment, allowing these cells to retain their essential characteristics outside the body. This innovative approach enables the rapid expansion of stem cells, making them suitable for early-stage diagnostics and the repair of injured tissues. Additionally, Ronawk focuses on preserving primary cells from patients for future use in reconstructive surgeries, thereby enhancing the efficiency and density of human cell growth for tissue generation and disease modeling.

Selmod, based in Basel, Switzerland, specializes in developing innovative therapies aimed at treating life-threatening, multi-drug resistant infections. The company focuses on discovering and advancing small molecules and peptides that target new mechanisms of action, addressing the urgent need for effective treatments in hospital settings where first-line therapies have failed. Selmod aims to provide second-line and last-resort options through a disruptive approach that incorporates dual modes of action to overcome resistance mechanisms. The company's lead candidates, SLM500, SLM100, and SLM300, have shown promise in preclinical studies, with market projections indicating a total available market exceeding $9 billion. With an experienced leadership team skilled in advancing clinical candidates for major pharmaceutical companies, Selmod plans to utilize funding to advance three IND-enabling candidates and six lead-optimized candidates into proof-of-concept stages.

MyoGene Bio focuses on creating innovative therapies for muscle diseases, with an initial emphasis on a gene-editing treatment for Duchenne muscular dystrophy. The company leverages advanced technologies to directly address the underlying causes of this condition, aiming to significantly improve disease progression. By targeting the fundamental issues associated with Duchenne muscular dystrophy, MyoGene Bio seeks to provide clinicians and patients with effective solutions that can lead to meaningful advancements in managing severe muscle disorders.

LIALT Laboratorio de Investigación Alternativa develops toxicological evaluations without the use of animals. LIALT replaces the use of animals through the use of three-dimensional tissues in conjunction with internationally recognized protocols that provide more specific information on the mechanisms of toxic action than that obtained in animals, offering a solution to the problem previously exposed.

Uniphage is a biotechnology company that specializes in developing innovative solutions to combat bacterial infections, with a focus on agriculture. It combines the power of bacteriophages, naturally occurring viruses that infect bacteria, with artificial intelligence to create precise and safe antimicrobial products. Uniphage's primary goal is to reduce the use of harmful fungicides, bactericides, and antibiotics in plant agriculture by providing more efficient and eco-friendly alternatives. By using AI algorithms to predict the effectiveness of bacteriophages against specific bacterial infections, Uniphage aims to accelerate the development of new pesticides, thereby minimizing risks to human health and the environment.

Stemloop is a biotechnology company focused on developing innovative cell-free biosensing products that enhance chemical and molecular testing processes. By utilizing genetically encoded sensing and response mechanisms, Stemloop creates accessible and actionable biosensors that are faster, cheaper, and easier to use than traditional laboratory tests. The company's mission is to address unmet needs in chemical sensing and detection, enabling medical professionals to deliver accurate and timely test results at reduced costs. Through its novel technology, Stemloop aims to unlock the potential of biology to respond effectively to various global challenges.

TissueLabs is the platform for creating organs and tissues in the lab. We offer biomaterials, equipment, and services to support tissue engineering and regenerative medicine. Our products are created to allow performing state-of-the-art research, from drug discovery to organ fabrication. Currently, we are focused on attending the academic life sciences market. In the future, our mission is to fabricate lab-grown tissues and organs, for both research and therapeutic applications.

MycoNourish specializes in the development of beneficial microbes tailored for specific crops, aiming to enhance agricultural production and add value for growers. By leveraging beneficial fungi that work in symbiosis with various crops, the company improves both yield and quality. MycoNourish focuses on customizing advanced strains of microbes to meet the unique needs of different crops, thereby enabling farmers to cultivate healthier produce. This innovative approach not only supports increased agricultural efficiency but also addresses challenges related to food wastage.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

BestHealth4U focuses on the research and development of advanced solutions for manufacturers of class 1 medical devices. The company specializes in medical adhesive technologies that aim to prevent skin injuries, accelerate healing, and enhance overall patient health. Its innovative and environmentally friendly adhesive products are designed to safeguard patients from skin damage, discomfort, irritation, and infections by improving the attachment of bandages, dressings, and medical devices to the skin. By providing effective solutions, BestHealth4U assists healthcare providers in reducing medical adhesive-related skin injuries and promoting the well-being of patients.

React4life is an Italian biotech company established in 2016 by Silvia Scaglione and Maurizio Aiello, following over 15 years of research and development. The company focuses on advancing biomedical research through its innovative technology, MIVO® (Multi In Vitro Organ), which represents a next-generation organ-on-a-chip system. This microphysiological platform allows researchers to simulate human biology more accurately in laboratory settings, addressing the limitations of traditional in vitro assays and animal testing. React4life's technology enhances the reliability and predictivity of various applications, including pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals. By enabling the cultivation of three-dimensional human-like tissues for in vitro testing, React4life aims to improve the effectiveness of laboratory experiments and promote ethical research practices.

Leucine Rich Bio is India's first and only company focused on microbiome-based genomics. It operates a genomics platform that analyzes the human microbiome, often referred to as the "Second Genome," to enhance understanding of its impact on health and wellness. The company offers a three-phase customized approach that includes nutritional recommendations and personalized supplements tailored to individual intestinal microflora. Its applications span various medical fields, including gastroenterology, endocrinology, oncology, mental health, and reproductive health, aiming to provide clinical solutions that promote overall human health. As interest in the microbiome continues to grow among researchers, clinicians, and consumers, Leucine Rich Bio is positioned at the forefront of this emerging area of precision medicine.

Umami Bioworks is a company focused on the discovery and development of a scalable platform for producing cultivated seafood, aiming to protect endangered marine species while providing consumers with sustainable seafood options. The company utilizes systems engineering to enhance the discovery and industrialization processes, facilitating local production that is both price competitive and environmentally responsible. Its innovative approach involves creating cell-based food products derived from fish cells and tissue, which are designed to be free from harmful substances such as mercury, antibiotics, microplastics, and ocean pollutants. By offering affordable, cell-cultured seafood and meat alternatives, Umami Bioworks addresses the growing demand for healthy and sustainable food choices.

Microbe Plus specializes in the development of innovative microbiological bio-products aimed at enhancing plant growth and protection. The company manufactures multi-strain probiotics for plants, which are formulated to safeguard crops against a wide range of pathogens, including diseases and pests. By utilizing carefully selected beneficial bacteria, Microbe Plus seeks to increase crop yields while minimizing the need for synthetic pesticides. Their mission is to create efficient and cost-effective solutions that support the health of various plants, including crops, orchards, flowers, and ornamental species, thereby contributing to sustainable agricultural practices.

Michroma Corporation is a biotechnology company that specializes in producing natural thermostable colorants derived from filamentous fungi through a fermentation process. Founded in 2019 and based in both San Francisco, California, and Rosario, Argentina, Michroma aims to replace synthetic pigments and those sourced from animals and plants with sustainable, naturally produced alternatives. The company harnesses synthetic biology to develop proprietary fungal strains that generate high-performance ingredients in bioreactors. Currently, Michroma is prototyping its innovative pH-stable and heat-stable food colorants in collaboration with leading food and beverage and cosmetic companies. Additionally, the company is exploring the production of mycoprotein and other ingredients, making strides in the sustainable ingredients market.

Matricelf is a biotechnology company focused on the development of advanced tissue and organ engineering solutions. Established in 2019 by Professor Tal Dvir from Tel Aviv University, the company utilizes a proprietary decellularization process to extract stromal cells and extracellular matrix (ECM) from small omental biopsy samples. This process produces a thermo-responsive hydrogel that incorporates reprogrammed induced pluripotent stem cells (iPSCs), which are differentiated into functional tissues using a patent-pending methodology. Matricelf's innovative approach aims to reduce the risk of implant rejection and includes the production of spinal cord implants designed for patients with traumatic spinal cord injuries. These implants help restore neuronal activity and motor functions, enabling patients to reintegrate into their communities and improve their daily lives. The company is committed to advancing medical treatments through its platform for autologous matrix and cell implants, addressing a wide range of medical conditions.

EcoPhage is a biotechnology company focused on developing and commercializing bacteriophage-based solutions for crop protection, specifically targeting bacterial plant diseases. With an estimated 10% of global food production lost annually due to these diseases, EcoPhage's innovative products leverage the unique properties of bacteriophages—viruses that specifically target bacteria—to provide effective and environmentally friendly alternatives to traditional pesticides. The company's proprietary platform, co-developed with the Weizmann Institute of Science, utilizes advanced screening and characterization methodologies to identify the most promising bacteriophage candidates. By offering nontoxic solutions that enhance plant yield and promote sustainability, EcoPhage aims to revolutionize the agricultural sector by reducing disease-related losses and transforming the bactericides market into a safer and more sustainable framework. Through its commitment to combating plant diseases, EcoPhage is poised to contribute significantly to the future of agriculture.

Byteflies is a Belgian-American wearable health company focused on developing innovative health applications through advanced technology. With offices in Antwerp, Belgium, and the San Francisco Bay Area, the company is strategically positioned near major life sciences and clinical research centers as well as the heart of digital innovation. Byteflies specializes in a wearable component sensor dot that records various biopotential signals, muscle activity, eye movement, and activity-related signals using an integrated inertial measurement unit. This technology is designed to assist pharmaceutical companies, researchers, and technology firms in transforming healthcare and enhancing patient outcomes. Byteflies aims to revolutionize healthcare by meticulously monitoring vital signs and leveraging data-driven insights.

KriyaBio specializes in developing innovative drug delivery solutions centered on its proprietary permeation enhancer, KB01. This advanced technology functions as a tight junction modulator, significantly improving the absorption of co-administered therapies. KriyaBio aims to replace traditional intravitreal injections of biologics with eye drops, promoting greater patient safety and compliance while reducing overall healthcare costs. Through its novel approach, the company addresses key challenges in drug delivery, enhancing the efficacy and convenience of therapeutic treatments.

Computational Life Inc. is a software development company based in Wilmington, Delaware, that creates innovative solutions for the healthcare sector. Founded in 2018, the company specializes in a Digital Avatar Platform (DAP) that simulates human and animal physiological systems using advanced mathematical models. This technology allows for detailed simulations of various bodily systems, including arterial and venous dynamics, heart function, microcirculation, and cerebrospinal fluid movement. By leveraging validated physical laws, Computational Life's platform aids healthcare professionals in predicting personalized patient outcomes and managing complex medical conditions. The software's ability to model the effects of medical treatments enhances decision-making in clinical settings, particularly for multisystemic diseases.

Tzofen is a biotechnology company focused on developing a novel biological platform aimed at treating various types of cancer. This innovative platform has demonstrated the ability to eliminate cancer growth both in vitro and in vivo, highlighting its potential to significantly impact cancer treatment. By advancing this technology, Tzofen seeks to contribute to saving millions of lives affected by cancer.

BINK Bio is working on developing biotech alternatives to reduce environmental damage. The company focuses on and technologies in the fields of biotech based dyes.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.

Vyasa Analytics is a company that specializes in providing an AI-powered platform tailored for life sciences and healthcare organizations. Its flagship product, Vyasa Layar, facilitates the integration and analysis of diverse data across various environments, including both cloud and on-premise sources. The platform offers a unified data landscape that allows users to explore their data through a suite of low-code, deep learning applications. Vyasa's technology incorporates scalable deep learning software that is capable of performing dark data analytics, neural concept recognition, and collaborative analytics, empowering organizations to extract insights from their enterprise data effectively and securely.

Onexio Biosystems is a research and development company. They offer HTS screens that typically utilize a single reporter cell type that lacks important confounding biology, including drug metabolism and paracrine and endocrine cell interactions. Their microDUO supports co-culture and multi-culture to improve human relevance in drug discovery and chemical screening.

Biomineral Systems focuses on environmental biochemical research and technology, offering a range of services aimed at tackling global environmental challenges. The company provides expertise in phosphorus management, soil organic carbon management, and soil quality enhancement. It also specializes in biogeochemical modeling for forest management, carbon trading and capture, mineral synthesis and characterization, and acid mine drainage solutions. By serving as environmental policy advisors to government entities and medium to large businesses, Biomineral Systems supports efforts to improve food security, promote environmental sustainability, and enhance biodiversity. Additionally, they develop and distribute decision-support tools that assist scientists and engineers in addressing complex environmental issues.

Amphasys is a technology company specializing in chip-based single-cell analysis technology that aims to simplify and expedite complex cell analyses, making them accessible at the point of use rather than solely in advanced laboratories. Founded in 2012 as a spin-off from Axetris AG, Amphasys developed its core technology in 2004 in collaboration with the Swiss Federal Institute of Technology Lausanne. Through extensive research across various cell types, it has demonstrated versatility for applications such as pollen and milk analysis. The technology streamlines processes by eliminating the need for time-consuming sample preparations, such as cell labeling, and reduces reliance on costly laboratory infrastructure. This enables clients to perform label-free analyses of single-cell characteristics, including cell size, morphology, viability, and differentiation. Amphasys has received recognition for its innovation, including the prestigious Swiss startup prize from the W.A. de Vigier Foundation in 2013.

mk2 Biotechnologies uses a synthesis process to design, synthesize, and research peptides and proteins. Their process allows the scalable and production of purity peptides and proteins for a range of applications.

Clara Biotech is focused on developing a platform technology for the isolation and purification of exosomes from small fluid samples, facilitating liquid biopsies for early detection of various diseases, including cancer and Alzheimer's Disease. Unlike traditional methods that require lengthy ultra-centrifugation, Clara's platform can extract pure and viable exosomes from any biofluid source efficiently. This innovative process enhances the potential for precision medicine by enabling targeted drug delivery directly to specific cells. Additionally, Clara Biotech's technology supports the development of unique liquid biopsy assays, improving the accuracy of disease detection and addressing challenges faced by biopharma companies in the medical field. Overall, Clara Biotech aims to advance research into clinical applications, bridging the gap between laboratory findings and patient care through its exosome-based solutions.

Convallo Bio focuses on developing advanced beneficial bacteria aimed at enhancing the health and wellness of humans, animals, and the environment. The company's molecular technology is designed to discover and deliver next-generation probiotics, which are intended to support various health applications. Through its innovative approach, Convallo Bio seeks to improve overall well-being by providing effective microbial solutions that address the needs of consumers and the ecosystem.

Onena Medicines is a biotechnology company focused on developing innovative biological therapies to meet the significant clinical needs of breast cancer and other serious orphan diseases. The company utilizes a proprietary antibody drug discovery platform that leverages artificial intelligence to create custom antibodies with high selectivity and specificity. This platform is designed to reprogram cancer cells and modulate the activities of a novel set of growth factors known as dual smad inhibiting protein dips, which are believed to contribute to cancer growth and metastasis. By doing so, Onena Medicines aims to provide physicians with access to new treatment options in areas where there is a lack of effective therapies.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, particularly those with perinatal brain injury. Its lead drug aims to promote the regeneration of myelin-producing oligodendrocytes and reverse white matter injury in premature infants. By providing effective treatments for all babies at risk of brain injury, Tellus Therapeutics seeks to enhance neurodevelopmental outcomes for these vulnerable children.

Aniluxx Biotechnology, Inc. is a biopharmaceutical company focused on developing innovative topical therapeutics for companion animals, specifically targeting skin diseases such as atopic dermatitis and osteoarthritis. Founded in 2019 and located in Chapel Hill, North Carolina, the company aims to improve the health and well-being of pets by utilizing a pipeline of topically formulated therapeutics based on compounds that have demonstrated safety and efficacy in humans. These therapeutics are designed to be easy to apply and virtually unnoticeable, minimizing the harsh side effects commonly associated with systemic medications. Through its efforts, Aniluxx Biotechnology seeks to provide effective and user-friendly treatment options for dogs, cats, and horses suffering from various skin conditions.

Mantle Biotech is a company focused on developing medical diagnostic devices that address unmet needs in global health. Founded in 2019 and headquartered in Cambridge, Massachusetts, the company specializes in engineering binding proteins capable of accurately identifying disease biomarkers in patient samples. Utilizing directed evolution to modify heat-stable proteins derived from microbes, Mantle Biotech produces high-quality binding proteins that are more stable and affordable than traditional reagents. These innovative reagents can be adapted for various diseases and testing formats, providing clinics with a reliable and cost-effective alternative to conventional diagnostic methods.

InvivoSciences specializes in phenotypic compound screening services that enhance drug discovery and repositioning. The company employs an innovative approach that combines tissue engineering technology with assay automation and sample miniaturization, facilitating rapid and cost-effective therapeutic discovery. Its mission focuses on developing engineered tissue-based assays that closely replicate the functions of living organisms, including humans and animals. By integrating patient-derived and gene-edited human samples, InvivoSciences aims to personalize the drug development process. The company utilizes advanced techniques in cell and tissue handling, tissue phenotyping assays, and computational biology, including artificial intelligence, to assist clinicians in swiftly identifying the safety and efficacy of treatments tailored to specific patient groups, thereby optimizing the preclinical phase before embarking on costly clinical trials.

MSL Pharma is a pharma company that performs ideation, analysis and identifies the solutions to treat diseases.

Byteflies is a Belgian-American wearable health company focused on developing innovative health applications through advanced technology. With offices in Antwerp, Belgium, and the San Francisco Bay Area, the company is strategically positioned near major life sciences and clinical research centers as well as the heart of digital innovation. Byteflies specializes in a wearable component sensor dot that records various biopotential signals, muscle activity, eye movement, and activity-related signals using an integrated inertial measurement unit. This technology is designed to assist pharmaceutical companies, researchers, and technology firms in transforming healthcare and enhancing patient outcomes. Byteflies aims to revolutionize healthcare by meticulously monitoring vital signs and leveraging data-driven insights.

CellSpring is a biotechnology company based in Zurich, Switzerland, focused on enhancing cell-based in vitro studies through innovative technology. Its flagship platform, 3D Bloom, allows for the rapid creation of biomimetic microtissues that are independent of cell type. This platform significantly improves upon traditional 3D cell culture methods by offering faster fabrication, greater reliability, and enhanced versatility. The microtissues developed using 3D Bloom are designed to serve various biological functions, including aiding clinicians in the early diagnosis of cancer. Through its advancements, CellSpring aims to facilitate fundamental improvements in the field of biotechnology and medical research.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, particularly those with perinatal brain injury. Its lead drug aims to promote the regeneration of myelin-producing oligodendrocytes and reverse white matter injury in premature infants. By providing effective treatments for all babies at risk of brain injury, Tellus Therapeutics seeks to enhance neurodevelopmental outcomes for these vulnerable children.

Phylomics Diagnostics is a biotechnology company that specializes in the detection of multiple cancers.

KJ scientific ensures testing and analysis of chemicals product to safety for human and environmental health.

Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2017. The company focuses on genetically programming mRNA to develop innovative therapies that enhance patient outcomes. Utilizing its mRNA programming technology, Strand Therapeutics creates gene therapies powered by synthetic biology, which include immunotherapies designed to stimulate cells to produce cancer-targeting proteins. This approach improves the immune system's ability to combat cancer by enabling precise control over the timing, location, and intensity of therapeutic protein expression. The technology leverages cell-type specific expression and responds to specific molecular signals, allowing for tailored therapeutic interventions.

Fluent BioSciences is a life science company focused on single-cell technology, specializing in molecular analysis of cells without the need for complex microfluidic instrumentation. Its proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), facilitates the rapid self-assembly of individual cells or molecules into millions of uniform partitions, allowing for sensitive and unbiased preparation of proteins and nucleic acids for sequencing applications. This innovative technology enhances accessibility to single-cell, molecule, and protein analysis, thereby broadening market access for researchers in biotechnology, pharmaceuticals, and academic institutions.

Haima Therapeutics is a pre-clinical stage biotechnology company dedicated to developing bio-inspired therapies for the treatment of bleeding and various blood-related disorders. The company focuses on creating platelet-inspired therapeutics that address conditions where platelets are crucial, such as thrombosis, inflammation, and cancer. Its innovative technology involves fully-synthetic nanoparticle-based hemostatic solutions designed to mitigate bleeding by enhancing the body's natural clotting mechanisms at the injury site. This approach aims to facilitate faster recovery for patients undergoing traumatic injuries, surgeries, and other blood-related health issues.

CrystalsFirst GmbH specializes in protein crystal stabilization techniques to enhance drug candidate screening, primarily serving pharmaceutical companies. Founded in 2018 and based in Marburg, Germany, the company offers innovative solutions such as SmartSoak technology for screening small molecule arrays, SmartLib for fragment-based drug discovery, and SmartRefine for automated crystallographic data refinement. Their MAGNET platform represents a significant advancement in drug discovery, integrating high-performance structural biology with generative AI and machine learning to identify novel molecules and druggable binding sites. By employing a "crystal structure first" approach, CrystalsFirst facilitates rational drug design and provides valuable insights into target interactions. The company's methodologies enable rapid access to diverse chemical scaffolds, thereby accelerating the discovery of effective therapeutic compounds and enhancing the overall efficiency of the drug development process.

Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.

Gateway Biotechnology is a drug development company focused on creating innovative solutions for hearing disorders. The company specializes in developing small molecule therapeutics aimed at treating hearing disabilities, utilizing advanced animal model systems for preclinical trials. These models are designed to address conditions such as noise-induced hearing loss and tinnitus. By providing drug candidates with established safety records, Gateway Biotechnology aims to enhance treatment options for patients suffering from various hearing impairments.

Environmental Quality Operations (EQO) specializes in advanced detection and monitoring solutions for invasive species in aquatic environments. Leveraging over a decade of experience in bioengineering and diagnostic development, EQO offers a unique automated sampling platform that enables users to monitor critical resources at risk of infestation. This system allows for programmable sampling intervals, with collected samples analyzed at EQO's laboratory to provide rapid results. The company's detection services utilize highly sensitive assays, capable of determining population activity and life cycle dynamics through biomarker analysis. In addition to monitoring, EQO is actively developing targeted biopesticide systems aimed at eradicating invasive species while minimizing impacts on non-target organisms. This integrated approach not only enhances early detection and robust analytics but also supports environmental protection and cost-effective remediation efforts.

BMSEED specializes in manufacturing advanced research tools that simulate stretch-induced neurotrauma in laboratory settings, aimed at enhancing the understanding of injury mechanisms and treatment options in both academic and pharmaceutical environments. The company's innovative neurotrauma model enables researchers to directly compare the electrophysiological activity of healthy cells with that of damaged cells following injury, thereby facilitating a more accurate evaluation of neuroprotective therapies. Additionally, BMSEED develops sustainable elastic electronic devices that integrate stretchable gold films for use in biomedical applications. These devices are designed to create compatible interfaces with biological tissues, improving interactions during traumatic brain injury surgeries and yielding better data for therapeutic, diagnostic, and research purposes.

Simbiótica Labs focuses on developing biological technology solutions aimed at enhancing crop productivity. The company creates organic products designed to optimize nutrient absorption in plants while preserving soil health. By revitalizing the root ecosystem and fostering synergy among microorganisms, Simbiótica Labs enables its clients to improve crop yields sustainably.

Scintia focuses on enhancing education and research in synthetic biology by providing innovative solutions designed to overcome barriers in biotechnology development. The company manufactures laboratory equipment and educational kits that facilitate hands-on learning experiences in genetic engineering. These kits include all necessary materials for conducting laboratory experiments, accompanied by comprehensive teaching guides for educators and students. By simplifying the educational process, Scintia enables users to engage in practical biological reactions, fostering a deeper understanding of synthetic biology concepts.

LIfT BioSciences is a biotechnology company based in London, England, founded in 2016. The company specializes in a novel allogeneic innate immuno-cell therapy platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). This platform enables the large-scale production of Immunomodulatory Alpha Neutrophils (IMANs) derived from induced pluripotent stem cells (iPSCs) for various therapeutic applications. LIfT BioSciences focuses on developing CAR neutrophil cell therapies that address the limitations of existing treatments for solid tumors. These therapies work by directly attacking tumors and indirectly enhancing the immune response, effectively transforming the tumor microenvironment to recruit additional immune cells for a more robust and lasting attack on the cancer. By employing proprietary enhancement media and genetic engineering, LIfT BioSciences aims to significantly increase the cancer-fighting capabilities of these engineered cells, potentially providing patients with greatly improved therapeutic outcomes.

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes microscopic worms for substance testing in pharmaceutical, chemical, and cosmetic industries. Their flagship product, the Caenorhabditis elegans-on-chip, integrates the use of these organisms for in vivo testing with a fully automated platform for in vitro culture, treatment, and analysis. This technology facilitates comprehensive toxicity testing, drug discovery, and anthelmintic testing applications, allowing clients to evaluate biological responses observable only at the whole-organism level. Nagi Bioscience aims to transform traditional testing methodologies by introducing its unique "Organism-on-Chip" technology.

Kernal Biologics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on designing and developing mRNA immunotherapies for diseases such as COVID-19 and cancer. Founded in 2016, the company utilizes its mRNA platform to enable specific cells to produce their own therapeutic agents. Kernal's innovative approach has garnered recognition, including awards from notable organizations like Amgen and NASA. The team behind Kernal Biologics has strong ties to prestigious institutions such as MIT and Harvard, along with extensive experience in the biotech sector, which underpins their expertise in the mRNA field.

Cellular Preservation Technologies operates in the field of synthetic biology, specializing in the preservation of biological cells and tissues through the innovative use of hyperbaric xenon gas and refrigeration. This advanced technology significantly enhances the durability of platelets, leading to increased supply and reduced waste, while also minimizing the risk of bacterial infections. By improving the efficacy of platelet preservation, the company enables hospitals and blood banks to deliver more effective and timely critical therapeutic services to patients.

Neurescence Inc. is a biotechnology company based in Toronto, Canada, specializing in the development of advanced optical imaging tools for brain diseases and therapeutics. The company offers two types of graded-refractive-index (GRIN) lenses designed for implantation in various regions of the brain and spinal cord, facilitating the transmission of fluorescence signals from neurons to imaging sensors. Additionally, Neurescence has developed Quartet, a miniature fluorescence microscope paired with data collection software optimized for neuronal calcium imaging. This system allows users to capture and analyze neuronal activity, providing time-stamped data for individual neurons. By enabling real-time monitoring of neuronal activities, Neurescence aims to enhance the understanding of brain functions and assist healthcare providers in diagnosing and treating conditions such as Alzheimer's, epilepsy, and depression. Incorporated in 2014, Neurescence continues to innovate in the field of biological imaging.

ReviveMed Inc is a precision-medicine company based in Cambridge, Massachusetts, founded in 2016. It specializes in a platform that utilizes data from small molecules or metabolites to derive actionable insights. The company's technology employs a network-based machine learning algorithm for the integrative analysis of untargeted metabolomic data alongside large-scale molecular information, which includes data from genes, proteins, drugs, and diseases. This innovative approach enables researchers to develop in-house therapeutics specifically targeting patients with liver diseases and related conditions, thereby aiming to improve health outcomes through the unlocking of metabolomic data's potential.

Bezoar Laboratories focuses on enhancing health for humans, animals, and the environment through innovative microbial solutions. The company develops probiotic medical and pharmaceutical products specifically designed to alleviate gastrointestinal issues, including bloating, constipation, and diarrhea. Their offerings are formulated to be free of gluten and dairy, and they maintain a low acidity level to ensure safety and effectiveness for consumers. By addressing these common health concerns, Bezoar Laboratories aims to improve overall well-being and promote healthier living.

Halo Life Science is focused on enhancing human health through innovative nutritional solutions. After three years of research and development, the company has introduced Naturalin™, a patent-pending phytonutrient designed to improve health and wellness in various food and beverage products. Naturalin™ is also available in nutritional supplement forms, making it accessible to a broader audience. The product has been validated for safety and effectiveness by researchers at the Dell Pediatric Research Institute at The University of Texas at Austin. Halo Life Science aims to provide simple, affordable, and effective food and nutritional supplements to support individuals dealing with chronic conditions, illnesses, and obesity, thereby reinforcing their commitment to elevating human potential.

Octagon Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibiotic medicines for life-threatening autoimmune diseases such as Pemphigus Vulgaris, Systemic Lupus, and Multiple Sclerosis. Founded in 2016, the company is dedicated to addressing multi-drug resistant infections and has shown effectiveness against critical pathogens identified by the World Health Organization. Octagon's targeted immunomodulator medicines aim to restore immune balance in patients with chronic autoimmune and inflammatory conditions by selectively targeting dysregulated immune cells, thereby helping patients avoid chronic immunosuppression. The company's operations are supported by a state-of-the-art facility adjacent to Harvard University, enabling efficient development of its therapies with minimal overhead. The management team comprises experienced scientists, clinicians, and entrepreneurs, contributing to a growing pool of research talent dedicated to advancing drug development.

General Biotechnologies identifies and develops undervalued discoveries in the life sciences. Their flagship program — Nivien Therapeutics — is a venture-backed oncology startup spun out of Harvard Medical School.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Structured Immunity is a protein engineering company focused on enhancing the safety and effectiveness of T cell receptor-based therapies. Founded in 2017 by David Hardwicke and Timothy Riley, the company leverages over 20 years of research from the laboratory of Brian Baker to develop advanced techniques in structural immunology. By optimizing T cell receptors, Structured Immunity aims to improve target specificity in cell-based cancer immunotherapy, thereby increasing drug efficacy and reducing side effects. The company provides pharmaceutical firms with the tools necessary to engineer innovative and patentable cellular cancer therapies that feature enhanced tumor targeting technology.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Nanosynex is a diagnostic test that checks bacterial resistance to antibiotics in a record time, using a phenotypic approach that involves microfluidic techniques and fluorescent-based analysis. The test helps doctors determine faster (same-day results) the most appropriate antibiotic treatment for their patients, helping them recover in a shorter time and preventing the spread of resistant bacteria in the environment. By limiting prolonged hospitalization, Nanosynex allows to save significant healthcare costs.

Hive is a crowdsourcing platform for biomedical PhDs ​

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Reminisciences develops a symbiotic treatment and a companion diagnostic for Alzheimer's disease through targeting the gut microbiome. Reminisciences exploits the crucial role of gut microbiota in human physiology and more specifically as we have discovered in Alzheimer's disease. There is no effective treatment for Alzheimer, despite 51 million patients in need. Our company develops 2 products: CerebralX, a symbiotic therapeutic treatment to restore altered gut microbiota and stop or delay Alzheimer's disease, and ReminiTest, a diagnostic based upon microbiota profiling.

GliaPharm SA is a Swiss biotechnology company focused on developing treatments for neurological and psychiatric disorders. Founded in 2016 and based in Geneva, the company utilizes its GliaX technology platform to identify drugs that target the activity of glial cells, which are essential support cells for neurons. This innovative approach aims to enhance brain metabolism in pathological conditions. GliaPharm employs high throughput screening technologies and conducts metabolic tests on both in vitro primary brain cell cultures and in vivo rodent models to evaluate compounds. The company addresses various neurological conditions, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS), and collaborates with contract research organizations to advance its drug development and regulatory processes. With a vision to lead in glia-mediated therapies, GliaPharm seeks to provide new neuroprotective agents that support cognitive function in patients.

Torigen Pharmaceuticals is dedicated to advancing cancer care for companion animals through innovative treatment options. Founded in 2013 and based in Farmington, Connecticut, the company focuses on developing immunotherapy solutions, particularly an experimental autologous cancer vaccine. This vaccine aims to activate the immune system to target specific tumor-associated antigens present on cancer cells, allowing for more effective detection and treatment of tumors. By providing alternatives to traditional, invasive methods such as surgeries and chemotherapy, Torigen seeks to improve the quality of life for pets facing cancer. The company builds on years of scientific research and is committed to pushing the boundaries of veterinary oncology.

Octagon Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibiotic medicines for life-threatening autoimmune diseases such as Pemphigus Vulgaris, Systemic Lupus, and Multiple Sclerosis. Founded in 2016, the company is dedicated to addressing multi-drug resistant infections and has shown effectiveness against critical pathogens identified by the World Health Organization. Octagon's targeted immunomodulator medicines aim to restore immune balance in patients with chronic autoimmune and inflammatory conditions by selectively targeting dysregulated immune cells, thereby helping patients avoid chronic immunosuppression. The company's operations are supported by a state-of-the-art facility adjacent to Harvard University, enabling efficient development of its therapies with minimal overhead. The management team comprises experienced scientists, clinicians, and entrepreneurs, contributing to a growing pool of research talent dedicated to advancing drug development.

ReviveMed Inc is a precision-medicine company based in Cambridge, Massachusetts, founded in 2016. It specializes in a platform that utilizes data from small molecules or metabolites to derive actionable insights. The company's technology employs a network-based machine learning algorithm for the integrative analysis of untargeted metabolomic data alongside large-scale molecular information, which includes data from genes, proteins, drugs, and diseases. This innovative approach enables researchers to develop in-house therapeutics specifically targeting patients with liver diseases and related conditions, thereby aiming to improve health outcomes through the unlocking of metabolomic data's potential.

LYF Rescue Drone is focused on enhancing avalanche victim recovery through innovative technology. The company has developed a drone-based search and rescue system that autonomously locates individuals buried in avalanches, addressing the limitations of traditional avalanche victim detectors, which are often slow and reliant on user skill. By automating the search process, LYF Rescue Drone significantly reduces the time it takes to find victims, thereby improving their chances of survival. The system not only identifies the location of the buried individual but also facilitates communication with rescue teams, streamlining the overall response to avalanche incidents. With around 150 fatalities from avalanches each year, this technology has the potential to save lives by minimizing human error and expediting rescue efforts.

Currently 10 metres of plastic wrapping must be manually removed from over 8 billion bales every year before use as livestock feed. Market research states that removing the plastic is ‘one of the most annoying jobs on the farm’. BioNet. have the solution, an edible biopolymer that saves the farmer time as the wrapping can be directly eaten from the bale. Furthermore, this reduces waste and the unique formulation allows for enhanced digestion leading to reduced methane emissions from livestock.

MesenFlow Technologies specializes in bio-imaging technology aimed at enhancing drug and cosmetic development. The company has created a platform that accelerates the drug development process by addressing challenges related to species cross-reactivity, animal testing, and understanding human diseases. Utilizing proprietary protocols on primary human cells, MesenFlow enables early definition of a drug's mechanism of action and translational relevance. The technology has also been adapted for the cosmetics and nutrition sectors, allowing for the assessment of the physiological impact of cosmetic or nutraceutical candidates during the early development phase. This approach supports environments where animal-free testing is essential and emphasizes the importance of understanding human biology in product development.

SUN bioscience SA is a bioengineering company based in Epalinges, Switzerland, founded in 2016. The company specializes in developing drug culture platforms that facilitate personalized medicine through the creation of patient-specific organoids, which are miniature 3D tissues derived from stem cells. Its flagship product, Gri3D, employs a proprietary high-throughput microwell array technology to produce these organoids, enabling reproducible image-based phenotypic screenings. By utilizing these organoids, SUN bioscience aims to enhance drug testing and the generation of safe, transplantable tissues, addressing current limitations in organoid culture related to scalability and automation. This innovative approach allows for early assessment of pharmaceutical efficacy and toxicity, paving the way for a new paradigm in drug discovery that moves beyond traditional animal or human testing.

TwentyGreen is a Swiss company that specializes in the production of probiotic feed supplements designed for sustainable animal farming. Founded in 2015 and based in Root, Switzerland, the company has developed a triple active probiotic that addresses key challenges in intensive animal farming, such as improving digestion, enhancing responses to plant-based feeds, and promoting better feed conversion ratios. This innovative product, rooted in research on intestinal health from the École Polytechnique Fédérale de Lausanne (EPFL), aims to optimize gut microbiota, which is vital for food metabolism and immune defense. By offering significant benefits, such as reduced disease incidence and lower ecological impact, TwentyGreen seeks to capture a 10% share of the rapidly growing global animal feed probiotic market, valued at over $4 billion annually. To achieve this, the company engages in extensive research and development in collaboration with academic partners, ensuring compliance with regulatory standards for both human food and animal feed.

SimplicityBio is a Swiss company founded in 2013 that focuses on biomarker discovery within the molecular diagnostics market. Utilizing an artificial intelligence-based platform, the company analyzes biological, clinical, and digital data streams to generate insights that facilitate the development process from target identification through pre-clinical and clinical phases. Its technology employs algorithms to explore biomarker signatures and identifies models based on user-defined criteria. SimplicityBio offers a range of services, including biomarker discovery and ranking, signature creation, and enhancement of existing signatures. The company also develops scientific innovations and intellectual property for its clients, positioning itself as a leader in the biomarker discovery sector. As of 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.

PathoVax LLC is a biotechnology company based in Baltimore, Maryland, founded in 2014. It focuses on the development of RGVax, an innovative vaccine designed to protect against human papillomavirus (HPV). RGVax is notable for being the first low-cost HPV vaccine that targets all clinically relevant types, including all 15 oncogenic strains and additional skin HPV types. This broad-spectrum approach addresses the limitations of existing vaccines, which primarily focus on a limited number of cancer-causing strains and often face low uptake due to incomplete coverage and associated social stigma. Established animal studies have demonstrated the protective efficacy of RGVax, positioning it as a suitable childhood vaccine and offering the potential for significant early market entry in a segment that could see higher acceptance and usage rates.

LifeJourney Books is dedicated to preserving and sharing the life stories of seniors through an accessible digital platform. As the senior population grows, there is an increasing desire to capture these invaluable narratives before they are lost. The platform enables users to create their life stories step by step, transforming their experiences into a beautifully printed book that serves as a lasting legacy for their loved ones. By offering an easy, enjoyable, and affordable way for seniors to document their lives, LifeJourney Books aims to connect generations and ensure that precious memories are not forgotten.

Cellphmed is a biotechnology company that specializes in developing innovative tools for genome analysis, focusing on untapped RNA biomarkers. By utilizing next-generation RNA sequencing technology, Cellphmed creates human cell barcodes that enhance the verification of human cell identity and quality. This technology allows researchers to access a significant portion of the genome, providing critical insights that support various applications in virology, oncology, and drug discovery. By facilitating the qualification of human cells, Cellphmed aims to advance the fields of diagnostics and biomedical research, making it easier for scientists to uncover valuable information from the complex landscape of the genome.